Parkman Healthcare Partners LLC bought a new stake in shares of MBX Biosciences, Inc. (NASDAQ:MBX – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 800,173 shares of the company’s stock, valued at approximately $44,170,000. MBX Biosciences comprises approximately 4.5% of Parkman Healthcare Partners LLC’s portfolio, making the stock its largest holding.
Other large investors also recently made changes to their positions in the company. CWM LLC boosted its position in shares of MBX Biosciences by 28.9% in the 4th quarter. CWM LLC now owns 1,784 shares of the company’s stock worth $56,000 after purchasing an additional 400 shares during the last quarter. Royal Bank of Canada increased its holdings in MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock valued at $49,000 after purchasing an additional 572 shares during the last quarter. California State Teachers Retirement System lifted its stake in MBX Biosciences by 64.7% in the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock valued at $55,000 after buying an additional 689 shares during the period. Strs Ohio lifted its stake in MBX Biosciences by 128.6% in the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after buying an additional 900 shares during the period. Finally, State of Wyoming bought a new position in MBX Biosciences during the second quarter worth about $58,000.
MBX Biosciences Trading Up 0.1%
MBX stock opened at $66.39 on Tuesday. The business’s 50-day moving average price is $59.86 and its two-hundred day moving average price is $42.22. The firm has a market cap of $3.20 billion, a PE ratio of -27.55 and a beta of 0.10. MBX Biosciences, Inc. has a 1-year low of $9.63 and a 1-year high of $72.64.
Analysts Set New Price Targets
Several research firms have recently issued reports on MBX. Mizuho boosted their target price on MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Citigroup reiterated an “outperform” rating on shares of MBX Biosciences in a research report on Tuesday, May 12th. Wall Street Zen lowered shares of MBX Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Truist Financial boosted their price objective on shares of MBX Biosciences from $70.00 to $88.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, Stifel Nicolaus set a $56.00 target price on shares of MBX Biosciences in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $77.00.
Get Our Latest Research Report on MBX Biosciences
MBX Biosciences Profile
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.
Featured Stories
- Five stocks we like better than MBX Biosciences
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding MBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MBX Biosciences, Inc. (NASDAQ:MBX – Free Report).
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
